Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Verrica Pharmaceuticals (Nasdaq: VRCA) will report fourth quarter and full year 2025 financial results and provide a corporate update on March 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Verrica Pharmaceuticals (Nasdaq: VRCA) will report fourth quarter and full year 2025 financial results and provide a corporate update on March 11, 2026.
The company will host a conference call and live webcast at 8:30 a.m. ET; dial-in details, conference ID VERRICA, and a 90-day webcast replay are available on the company website.
Details
News Market Reaction – VRCA
On Mar 5, the day this news came out, VRCA closed 2.44% below the previous close.
Data tracked by StockTitan Argus for the Mar 5 session.
Key Figures
- Earnings call time
- 8:30 a.m. ET
- Scheduled conference call on March 11, 2026
- Earnings call date
- March 11, 2026
- Fourth quarter and full year 2025 results
- Fiscal year-end
- December 31, 2025
- Period covered by upcoming financial results
- Domestic dial-in
- 1-800-343-4136
- US phone number to join earnings call
- International dial-in
- 1-203-518-9843
- International phone number to join earnings call
- Dial-in lead time
- 10 minutes
- Requested time before start of call to register
- Webcast replay period
- 90 days
- Length of time replay will be archived on website
Historical Context
-
Participation in TD Cowen healthcare conference with webcast access for investors.
-
Appointment of seasoned Chief Commercial Officer to expand YCANTH commercialization.
-
Launch of YCANTH in Japan by partner Torii for molluscum contagiosum.
-
First patient dosed in global Phase 3 program for common warts.
-
$50M private placement to repay debt and extend expected cash runway.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call can also be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only healthcare professional-administered treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide, formerly known as LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.